The partners aim to establish and conduct programs and activities in agricultural research, technology, information transfer, and economic development.
BGI CEO Ye Yin says that mapping variation within the human genome will bring a "big data revolution" to healthcare, Wired UK writes.
BGI is seeking an IPO on a Shenzhen-based stock exchange, but the timing of when this might occur is unclear, FinanceAsia reports.
Several new laboratories started to offer NIPT locally in 2015, and some providers have been shifting to less-expensive non-NGS platforms.
Pacific Biosciences' launch of the Sequel instrument, Oxford Nanopore Technologies' MinIon instrument, and 10X Genomics' technology excited the market in 2015.
Only about 5 to 6 percent of women in China, mostly in urban areas, currently obtain NIPT, but their number is expected to increase quickly in coming years.
The partners will create, sequence, and characterize millions of new rice gene alleles, focusing on proprietary rice lines with high-density genome variation.
The company plans to lay off 145 employees at its Mountain View headquarters, as well as 15 in San Jose, 13 in Sunnyvale, and six in San Francisco.
Going forward, Complete Genomics will focus on clinical research and support BGI's noninvasive prenatal testing business as well as the launch of its benchtop sequencer in China.
The organizations will use genomics to further research in evolution, ecology, agriculture and aquaculture, and science education and popularization.
In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.
British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.
An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.
The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.